Australia's largest stock trading and investment forum Australia's #1 stock forum

PBP

Click for more information

0.00%

$2.98 probiotec limited

Yeh, I agree your numbers weren't too far off. Also, I am...

First 5 Last

Share
Profile

Follow
Fire Bull

1,252 Posts.

19

25/08/17

09:44

Post #: 26749182
Share

Originally posted by Wini ↑

Hey mate, I just ran a quick comparison against my numbers. Branded manufacturing was pretty close, contract manufacturing had lower revenue but the higher margins meant earnings were close, but there was an $800k earnings gap from weight loss/obesity.

Revenue was a touch lower, but the big miss came from a margin decline. While it's disappointing, I have to admit it isn't surprising given I suspected PBP were investing ahead of the curve in sales and marketing for weight loss/obesity. The change from licensing to what I assume is direct sales would have a short term effect as well.

But definitely not all doom and gloom. Minimal growth, but the share price wasn't pricing in high growth anyway. Cash flow is solid, dividend maintained and outlook is strong. Unlikely to be a catalyst until the half year, but happy to hold for now.

Expand

Yeh, I agree your numbers weren't too far off. Also, I am reasonably inclined to trust the commentary regarding rationalising product lines, timing issues with new contracts coming online and removing licensing fees to expand the pharmacy channel given management has significant skin in the game.

PBP Price at posting: 50.0¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 4 more messages in this thread...

First 5 Last

Add PBP (ASX) to my watchlist